The pharmacological inhibition of ANGPTL3 with monoclonal antibodies shows their safety and efficacy in lowering both LDL-C and triglycerides, thus slowing atherosclerosis progression [16]. The gene discussed is ANGPTL3; the disease is atherosclerosis.